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The Novel ATM-Related Protein TRRAP Is an Essential
Cofactor for the c-Myc and E2F Oncoproteins
centered at amino acid 135 in human c-Myc. Recent
studies have shown that deletions or single point muta-
tions within MbII can eliminate the transformation poten-
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tial of c-Myc (Brough et al., 1995; MacGregor et al.,*Department of Molecular Biology
1996). In addition to transformation, other functions ofPrinceton University
c-Myc have been shown to be entirely dependent onPrinceton, New Jersey 08544-1014
MbII. These include the induction of apoptosis (Askew²ABL Basic Research Program
et al., 1991; Evan et al., 1992), the ability of c-Myc toNCIÐFrederick Cancer Research and
block differentiation (Freytag et al., 1990), and the re-Development Center
pression of transcription of several genes (Penn et al.,Frederick, Maryland 21702
1990a; Penn et al., 1990b; Freytag and Geddes, 1992;
Li et al., 1994). These studies suggest that an under-
standing of the mechanism by which c-Myc functionsSummary
would be significantly advanced by determining the
function of the essential MbII region. Given the modular-The c-Myc and E2F transcription factors are among
ity of transcription factors, it initially seemed plausiblethe most potent regulators of cell cycle progression
that MbII might serve as a transactivation domain. How-in higher eukaryotes. This report describes the isola-
ever, deletion of MbII fails to eliminate the transactiva-tion of a novel, highly conserved 434 kDa protein, des-
tion potential of c-Myc (Kato et al., 1990; Bello-Fernan-ignated TRRAP, which interacts specifically with the
dez et al., 1993; Brough et al., 1995), suggesting thatc-Myc N terminus and has homology to the ATM/PI3-
transformation by c-Myc requires an N-terminal functionkinase family. TRRAP also interacts specifically with
more specific than recruitment of basal transcriptionthe E2F-1 transactivation domain. Expression of trans-
factors.dominant mutants of the TRRAP protein or antisense
We formulated the hypothesis that MbII is critical be-RNA blocks c-Myc- and E1A-mediated oncogenic
cause it facilitates the interaction of c-Myc with an es-transformation. These data suggest that TRRAP is an
sential cofactor. As an initial test of this hypothesis, weessential cofactor for both the c-Myc and E1A/E2F
analyzed the ability of the c-Myc N terminus to functiononcogenic transcription factor pathways.
as a dominant inhibitor of transformation by full-length
c-Myc. These experiments demonstrated the presenceIntroduction
of an essential, titratable factor that is sequestered by
the addition of excess c-Myc N terminus (in the form of aSince its initial discovery, considerable evidence has
GAL4 fusion protein) (Brough et al., 1995). Other studiesaccumulated implicating the c-myc oncogene in human
have arrived at similar conclusions, using either a GAL4-cancer. In Burkitt's lymphomas and certain AIDS-related
B-Myc fusion or a c-Myc mutant lacking the C-terminal
lymphomas, the c-myc gene is translocated to one of
dimerization domain (Resar et al., 1993; MacGregor et
the immunoglobulin gene loci, and amplification of
al., 1996). Most importantly, we found that the dominant
c-myc has been described in approximately 15% of all
inhibitory effect of the c-Myc N terminus was abolished
human tumors (Cole, 1986; Henriksson and LuÈ scher, by deletion of MbII (Brough et al., 1995). More direct
1996). A role for c-myc in the control of normal cell cycle
evidence for the existence of a specific MbII-interacting
progression has also been firmly established by studies
factor came from an analysis of nuclear extracts in which
of fibroblasts that are genetically deficient for the c-myc the dominant inhibitory protein containing the c-Myc N
gene, which have a dramatically prolonged cell cycle
terminus was shown to form a novel complex that was
(Mateyak et al., 1997).
dependent on the presence of MbII (Brough et al., 1995).
Both the normal and oncogenic functions of c-myc
The oncogenic and biological functions of c-Myc re-
are presumed to rely on the ability of its protein product markably parallel those of the adenovirus E1A protein,
(c-Myc) to act as a sequence-specific transcription fac- including an ability to transform and immortalize cells,
tor, since disruption of the c-Myc B/HLH/LZ domain block differentiation,and both activate and repress tran-
abolishes its oncogenic capacity (Stone et al., 1987; scription (Brockmann and Esche,1995). However, unlike
Amati et al., 1993). However, in addition to the DNA- c-Myc, E1A does not function directly as a DNA-binding
binding domain, the N-terminal region of c-Myc is also transcription factor, but instead binds to several nuclear
essential for transformation. This region encompasses proteins to indirectly control the cell cycle and transcrip-
several discrete blocks of amino acids that are con- tion factor activity. The control of the cell cycle by E1A is
served inMyc proteins throughout evolution (Cole, 1986; largely mediated by binding to the Rb tumor suppressor,
Henriksson and LuÈ scher, 1996). Based on this conserva- which regulates the activity of the E2F family of tran-
tion, these regions have been referred to as Myc homol- scription factors (Nevins et al., 1997). E1A binding to Rb
ogy boxes. Among the major conserved regions of the prevents Rb from inhibiting E2F activity. Like c-Myc,
N terminus, the most critical for oncogenic transforma- E2F can promote entry into S phase, transform cells,
tion is Myc box II (MbII) (Stone et al., 1987), which is induce apoptosis, and activate transcription (Nevins et
al., 1997). Rb binds to the transactivation domain of E2F,
which prevents transcriptional activation of E2F target³To whom correspondence should be addressed.
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genes and converts E2F into a direct repressor (Nevins
et al., 1997). While the transactivation domain is essen-
tial for most biological activities of E2F (Nevins et al.,
1997), positive effectors that are recruited by this do-
main have not been defined. The connection between
the oncogenic functions of E1A/E2F and c-Myc has re-
mained elusive. However the c-Myc N terminus can in-
hibit oncogenic transformation by E1A, suggesting that
some common factor may participate in both pathways
(Brough et al., 1995; MacGregor et al., 1996). Consistent
with this interpretation, the inhibition of E1A-mediated
transformation was dependent on the MbII domain of
the c-Myc N terminus (Brough et al., 1995).
Since the dominant inhibition assays and MbII-spe-
cific nuclear complexes provided strong evidence for
the existence of an essential effector of c-Myc function,
we initiated the biochemical purification of this cofactor
and isolated the corresponding cDNA, which we have
designated the TRRAP gene, for transformation/tran-
scriptiondomain±associated protein.TRRAP isconserved
in evolution and is essential for oncogenic transforma-
tion of mammalian cells. Identification of the TRRAP
protein provides a novel connection between the c-Myc
and E2F transcription factors and a new avenue to define
their oncogenic functions.
Figure 1. Affinity Purification of a Nuclear Protein Interacting with
the c-Myc Amino Terminus
The FLAG-GAL4/Myc and FLAG-GAL4 proteins were produced as
Results nuclear extracts from Sf9 cells and mixed with heat-treated HeLa
nuclear extract and anti-FLAG monoclonal antibody. After capture
Affinity Purification of a c-Myc-Interacting on Protein A/G beads, beads were washed and the bound proteins
eluted by the addition of FLAG peptide. Aliquots from indicatedNuclear Protein
stages of a large-scale binding reaction were run on an 8% SDS/We have previously demonstrated that one or more un-
polyacrylamide gel, and proteins were visualized by silver staining.known nuclear proteins associate with the c-Myc N ter-
Lanes 1±3, aliquots of the binding reaction, postbead supernatant,
minus and that this interaction is dependent on the pres- and bead wash for a reaction containing FLAG-GAL4, HeLa cell
ence of MbII (Brough et al., 1995). To affinity purify this nuclear extract, and anti-FLAG antibody. Lane 4, FLAG peptide
MbII-dependent, c-Myc-interacting protein(s), a fusion eluate from this reaction. No c-Myc interacting nuclear factor
(TRRAP) or FLAG-GAL4/Myc are visible. Lane 5±7, aliquots of theprotein containing c-Myc amino acids 1±262 and the
binding reaction, postbead supernatant, and bead wash for a reac-GAL4 DNA-binding domain was tagged with the FLAG
tioncontaining FLAG-GAL4/Myc, HeLa cell nuclear extract, and anti-epitope (Hopp et al., 1988). As a control, an independent
FLAGantibody. Lane 8, eluate from this reaction. The eluate contains
fusion protein containing only the FLAG-GAL4 portion a protein of 60 kDa corresponding to the FLAG-GAL4/Myc fusion
was produced. The FLAG-GAL4 and FLAG-GAL4/Myc protein (labeled FGM) and a large protein, designated TRRAP, that
proteins were produced as nuclear extracts from bacu- migrates near the top of the resolving gel. The identity of the FLAG-
GAL4/Myc band was confirmed by Western blotting (data notlovirus-infected insect cells. These extracts were mixed
shown). A nonspecific protein associated with the Protein A/G beadswith nuclear extract from HeLa cells, which was pre-
in both binding reactions (ns in lanes 4 and 8). Molecular weightviously shown to contain the N-terminal interacting fac-
(indicated in kilodaltons at left) was determined by coelectro-
tor(s). It was determined that the factor was stable to phoresis of protein MW marker (Novex).
heating of HeLa cell nuclear extracts to 558C for 10 min
(data not shown). Since this treatment resulted in the
precipitation of approximately 80% of the nuclear pro- it remains possible that a third, unresolved polypeptide
links c-Myc to the large polypeptide visible in Figureteins, it was used as an initial purification.
Affinity purification of the c-Myc interacting protein 1, the most straightforward interpretation is that the
interaction is direct. The large protein identified here haswas achieved by large-scale capture and elution of the
multiprotein complex with FLAG peptide (Figure 1). Fol- been designated TRRAP based on the characterization
presented in the remainder of this study. The bindinglowing separation by SDS-PAGE and silver staining, the
initial binding reaction contains a wide range of polypep- specificity of this large unknown polypeptide for the
c-Myc N terminus was demonstrated by its absence intides, reflecting the complexity of the nuclear extract
(Figure 1, lane 5). Surprisingly, the eluate from the FLAG- eluates from a parallel reaction in which FLAG-GAL4 was
used in place of FLAG-GAL4/Myc (Figure 1, lanes 1±4).GAL4/Myc extracts contained only two specific poly-
peptides, one of which is the 60 kDa FLAG-GAL4/Myc
protein (labeled FGM, lane 8). The only other prominent TRRAP Polypeptide Sequence and cDNA Isolation
Approximately 200 pmol (80 mg) of the c-Myc bindingpolypeptide in the eluate migrated well above the 217
kDa marker (Figure 1, lane 8). No other specific polypep- protein was isolated and processed for automated mi-
crosequencing. Reliable amino acid sequence was ob-tides were visible even when eluates were resolved by
higher percentage SDS-PAGE (data not shown). While tained from ten peptides. Degenerate oligonucleotides
TRRAP, an Essential c-Myc Cofactor
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Figure 2. Sequence of the Human TRRAP Protein
Sequences of TRRAP cDNA clones identified as described in the text were used to determine the predicted 3828±amino acid sequence of
the human TRRAP protein. A bipartite nuclear localization signal at 2029±2046, a potential leucine zipper at 3403±3424, and two TPR regions
at 2752±2785 and 3088±3121 are underlined. The region of TRRAP with homology to the ATM/PI-3 kinase family is boxed.
were designed based on the sequence of two of the collection of approximately 60 human and mouse ESTs.
Fortuitously, one of the human ESTs corresponding topeptides and then used to probe a random-primed cDNA
library from HeLa cells. From 5 3 105 phage, a single the TRRAP cDNA had been included in a study that
randomly mapped the chromosomal location of severalplaque hybridized to both degenerate oligonucleotides.
Translation of the nucleotide sequence demonstrated hundred unknown cDNAs (Berryet al., 1995). The TRRAP
gene corresponds to the EST NIB217, and this gene isthat the polypeptide it encoded contained both of the
peptides on which the screen was based, as well as located on human chromosome 7 at q21.3-22.1.
another of the ten peptides derived from the affinity-
purified protein. Probes were derived from either end of TRRAP Is Highly Conserved in Evolution
The predicted amino acid sequence of human TRRAPthe original cDNA insert and used to rescreen the same
library for clones that extended beyond the original iso- was compared to protein databases, revealing unique
homologs in four other eukaryotes (Figure3). The TRRAPlate. A complete 12.4 kb cDNA can be reconstructed by
aligning a minimum of seven of these partial cDNAs homologs are all defined as predicted open reading
frames found by genome sequencing projects in S.cere-(data not shown). This assembled cDNA encodes a novel
protein of 3828 amino acids (Figure 2), which contains visiae, S. pombe, C. elegans, and A. thaliana. Conse-
quently, no functional data have been reported for anyall ten of the peptides obtained by microsequencing
the original polypeptide. When used to search the EST of the TRRAP homologs. Remarkably, the ORFs from
all five species predict very large proteins that are nearlydatabase, the extreme 39 end of this cDNA matched a
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Figure 3. TRRAP Is Conserved in Evolution and Related to Proteins of the ATM/PI-3 Kinase Family
(A) The human TRRAP protein was compared to the S. cerevisiae homolog in 200±amino acid blocks using the LALIGN algorithm (Huang and
Miller, 1991). Shading indicates the percentage of identical amino acids between the two proteins within each block.
(B) The TRRAP homologs from human, S. cerevisiae, S. pombe, A. thaliana, and C. elegans (accession numbers P38811, O10064, AC003952,
and Z69902, respectively) were aligned using the LALIGN algorithm (Huang and Miller, 1991). The percent of identical and similar amino acids
between each pair of TRRAP homologs is indicated.
(C) Selected blocks of conservation from the C-terminal 300 amino acids of the human and S. cerevisiae TRRAP homologs are aligned with
similar regions from the ATM/PI-3 kinase family using the CLUSTALW v.1.6 algorithm (Myers and Miller, 1988) and conserved amino acids
highlighted with BOXSHADE. The DXXXXN and DFG motifs that constitute part of the catalytic site in the ATM/PI-3 kinase±related proteins
are underlined, and these motifs are missing from TRRAP.
identical in size. The conservation among TRRAP homo- of the protein (Figure3A). HumanTRRAP is z25% identi-
cal to its homologs in pairwise comparisons using thelogs is not due to a small protein domain containing a
common structural motif, since homology can be identi- LALIGN algorithm (Figure 3B). When conservative substi-
tutions are allowed, the total similarity between TRRAPfied in numerous colinear blocks throughout the length
TRRAP, an Essential c-Myc Cofactor
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proteins in different species is 55%±60%. Our studies and TRRAP was abrogated by deletion of MbII (Figure
4B, upper panel, lanes 5 and 6). Equivalent immunopre-of the S. cerevisiae TRRAP protein (designated TRA1p)
indicate that it is essential for vegetative growth (data cipitation of the FLAG-tagged proteins was confirmed
by probing a fraction of each sample with anti-FLAGnot shown).
(data not shown). A weak interaction between TRRAP
and c-Myc D129±145 has been observed upon longerTRRAP Is Related to the ATM/PI-3 Kinase Family
exposures. Thus, the interaction of the c-Myc protein
Beyond the identification of closely related TRRAP ho-
with TRRAP requires a domain that is essential for cellmologs in different species, database searches also re-
transformation, and this in vivo binding parallels thevealed that the C-terminal portion of TRRAP exhibits a
MbII-dependent dominant inhibitory activity of the c-Mycsignificant homology to the PI-3 kinase domain of the
N-terminal fusion protein that initially provided an assayataxia telangiectasia mutated (ATM) protein family (Fig-
for the presence of TRRAP (Brough et al., 1995).ure 3C). In TRRAP, as in all of the diverse members of
Deletion mutants of the FLAG-GAL4/MYC protein indi-the ATM family, the homology is confined to the extreme
cated that a region N-terminal of amino acid 110 inC terminus of these very large proteins (Enoch and Nor-
c-Myc was also required for TRRAP interaction (databury, 1995; Zakian, 1995; Lavin and Shiloh, 1996). The
not shown). To define this secondcritical region, a serieshomology extends over z300 amino acids, and there
of deletion mutants was created in the FLAG-tagged
are numerous residues that are conserved among all
c-Myc protein. These deletions spanned amino acids
members of the family, including TRRAP. Curiously, the
1±110, 20±48, 24±31, 33±38, or 38±48 in the c-Myc pro-
amino acids that map to the catalytic site of the ATM/
tein. As a test of the biological activity of these c-Myc
PI-3 kinase family proteins are not found in TRRAP,
mutants, c-myc/H-ras cotransformation assays were
although flanking residues are conserved (Figure 3C;
performed using primary rat embryo fibroblasts (REFs)see Discussion for further detail).
(Figure 4A). In addition to the deletion mutants in theAs predicted by our previous studies (Brough et al.,
c-Myc 1±110 region, the MbII deletion mutant (D129±1995), TRRAP is almost exclusively nuclear in localiza-
145) was also tested. As expected,deletion of MbII elimi-tion (data not shown) and contains a bipartite nuclear
nated the transformation potential of c-Myc, and four oflocalization signal consensus at amino acids 2029±2046.
the other N-terminal deletion mutants (D1±110, D20±48,Beyond the ATM/PI-3 kinase domain, TRRAP contains
D24±31, and D38±48) either eliminated or severely re-two other motifs that could prove functionally relevant.
duced transformation (Figure 4A). In contrast, one of theThere are eight LXXLL sequences dispersed throughout
smaller deletion mutants, D33±38, retained transforma-
the protein, a motif associated with several transcrip-
tion potential that was equal to that observed with wild-
tional coactivators (Heery et al., 1997; Torchia et al.,
type c-Myc. These mutants were then tested in 293
1997). TRRAP also includes two TPR motifs located near
cells for their ability to interact with endogenous TRRAP.
the C terminus. In general, the TPR motif is found in
Following transient transfection of 293 cells, the various
proteins that arecomponents of large multisubunit com-
c-Myc proteins were immunoprecipitated, and the pre-plexes (Sikorski et al., 1990).
cipitates were probed for either the FLAG epitope±
tagged c-Myc proteins (Figure 4C, bottom) or for TRRAP
TRRAP Binding Requires Domains of c-Myc (Figure 4C, top). In support of a role for TRRAP in cellular
that Are Critical for Transformation transformation by c-Myc, only the single c-Myc mutant
The experiments presented above demonstrate an as- capable of transformation, D33±38, was competent for
sociation between TRRAP and the c-Myc N terminus as TRRAP interaction. These results suggest that c-Myc
a GAL4 fusion protein.To confirm that an interaction with has an extended domain of interaction with TRRAP,
endogenous TRRAP requires the critical MbII domain of requiring both MbII and a more N-terminal domain. An
c-Myc, duplicate plates of 293 cells were transiently alternative explanation is that many different N-terminal
transfected with an expression vector directing produc- c-Myc mutations can induce a global change in confor-
tion of a c-Myc protein that included an N-terminal FLAG mation that isunfavorable for TRRAP binding. The bipar-
epitope. A similar construct encoding a FLAG epitope± tite nature of the TRRAP interaction domain on c-Myc
tagged version of the transformation-defective c-Myc is similar to that seen for the interaction of c-Myc with
mutant lacking MbII (D129±145) was also transfected. other proteins, including Rb, TBP, and Bin1 (Hateboer
Transfection of vector alone served as a negative con- et al., 1993; Sakamuro et al., 1996).
trol. Cells were lysed using native conditions at 24 hr To determine whether the association between TRRAP
posttransfection (Harlow et al., 1986), and the equivalent and c-Myc can be observed with endogenous c-Myc,
expression of the FLAG-tagged c-Myc proteins was coprecipitation studies were conducted using the hu-
demonstrated by probing Western blots of the lysates man colon carcinoma line COLO 320, which produces
with anti-FLAG antibodies (Figure 4B, lower panel, lanes high levels of c-Myc protein (Alitalo et al., 1983). COLO
2 and 3). The remaining lysate was immunoprecipitated 320 cells were lysed using a protocol designed for the
using anti-FLAG antibodies, resolved by SDS-PAGE, efficient extraction of endogenous c-Myc (Sommer et
transferred to nitrocellulose, and blotted with antisera al., 1998), and the c-Myc protein was immunoprecipi-
against the TRRAP protein. The results showed that the tated using antibodies directed against its obligate part-
endogenous TRRAP protein was specifically precipi- ner, Max. Antibodies to Max were utilized because anti-
tated from cells expressing FLAG-tagged c-Myc, but bodies directed against c-Myc itself might block the
not from cells expressing the control vector that only interaction between c-Myc and TRRAP. The anti-Max
encodes the FLAG epitope (Figure 4B, upper panel, precipitate contained the c-Myc protein (Figure 4D,
lower panel), and the same precipitate also containedlanes 3 and 4). Strikingly, the in vivo interaction of c-Myc
Cell
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Figure 4. TRRAP Interaction Correlates with
Cellular Transformation by c-Myc
(A) Primary rat embryo fibroblasts (REFs)
were transfected with expression vectors for
H-ras and one of various FLAG-tagged c-Myc
proteins. The number of transformed foci are
expressed as a percentage of the number of
foci obtained in the same assay for wild-type
c-Myc. The totalnumber ofplates assayed with
each c-Myc protein was as follows: 8 for
FLAG/c-Myc, 4 for D129±145 and D1±110,
and 6 for D20±48, D24±31, D33±38, and
D38±48.
(B) 293 cells were transiently transfected with
expression vectors for either FLAG epitope±
tagged mouse c-Myc protein or an MbII dele-
tion mutant (D129±145). Lysates from dupli-
cate transfections were prepared, and a
fraction of each lysate (5%) was resolved in
8% SDS-PAGE and Western blotted with
anti-FLAG antibody (bottom). The remainder
of each lysate was immunoprecipitated with
anti-FLAG antibody, resolved on 4% SDS-
PAGE, and Western blotted with anti-TRRAP
antibodies (top). Lane 1, lysates from cells
transfected with a vector expressing the
FLAG epitope alone. Lanes 2 and 3, lysates
from cells expressing FLAG-c-Myc. Lanes 4
and 5, lysates from cells expressing FLAG-c-
Myc(D129±145). Size (in kilodaltons) at the left
was determined by coelectrophoeresis of
protein MW markers (Novex).
(C) 293 cells were transiently transfected with
CMV-driven expression vectors for FLAG-tagged full-length mouse c-Myc or N-terminal deletion mutants of this construct, as indicated.
Lysates were prepared and c-Myc proteins immunoprecipitated with anti-FLAG antibody. Precipitated proteins were resolved by SDS-PAGE
and Western blotted for either TRRAP (top) or the FLAG epitope of the transfected c-Myc proteins (bottom).
(D) Cells from the human colon carcinoma line COLO 320 were lysed and subjected to immunoprecipitation using either rabbit anti-Max
antisera or normal rabbit immunoglobulin as a control. Precipitates were resolved by 8% SDS-PAGE and blotted for either c-Myc (using the
anti-human c-Myc monoclonal 9E10) or for TRRAP as indicated.
the endogenous TRRAP protein (Figure 4D, upper panel). alone (labeled CbF) was used as a control. At 12±14
days posttransfection, the number of transformed fociThis observation indicates that theassociation observed
with transfected c-Myc also occurs with endogenous per plate was determined and expressed as a percent-
ageof the foci obtained onplates transfected with equiv-c-Myc. Neither c-Myc nor TRRAP were detectable in con-
trol immunoprecipitates for COLO 320 cells (Figure 4D). alent amounts of the vector control. Expression of
TRRAP amino acids 270±599 or 856±1134 had no signifi-
cant effect on transformation of REFs by c-myc and
Transdominant Mutants and Antisense TRRAP H-ras. In marked contrast, expression of TRRAP amino
Inhibit Transformation by c-Myc acids 1261±1579 or 3402±3828 inhibited transformation
Since the MbII-dependent binding of TRRAP paralleled by 92% and 52%, respectively. Interestingly, the most
the dominant inhibitory activity of the c-Myc N terminus inhibitory domain of TRRAP (amino acids 1261±1579)
(Brough et al., 1995), it was important to test directly contains a leucine-rich motif similar in position to a leu-
the link between TRRAP and the biological activity of cine-rich domain of ATM that also functions as a domi-
c-Myc. This same strategy was employed to identify nant inhibitor (Morgan et al., 1997). Whether the in-
dominant inhibitory fragments of TRRAP capable of hibitory mutants of TRRAP function by directly binding
blocking c-Myc function. The c-myc/H-ras transforma- c-Myc or by sequestration of a downstream component
tion assay with primary REFs was supplemented with in the c-Myc/TRRAP pathway remains to be determined.
expression vectors directing the production of various As a second method of interfering with endogenous
TRRAP protein fragments. Partial TRRAP cDNAs encod- cellular TRRAP function, antisense RNA was used to
ing amino acids 270±599, 856±1134, 1261±1579, or 3402± block the synthesis of TRRAP protein. A fragment of the
3828 were cloned into a CMV promoter±driven mamma- TRRAP cDNA was cloned into a CMV expression vector
lian expression vector downstream of sequences for the in antisense orientation and cotransfected with c-myc
FLAG epitope. The N-terminal FLAG epitope provided and H-ras in a transformation assay. The empty vector
the initiation codon for these proteins, as well as a served as a control. Expression of TRRAP antisense
method for assessing protein production, and the pro- inhibited focus formation by 90%, relative to the control
teins were expressed at relatively similar levels (Figure level (Figures 5C and 5D). In addition to the results ob-
tained with transdominant mutants of TRRAP, this anti-5A). The CMV vector containing the FLAG sequences
TRRAP, an Essential c-Myc Cofactor
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Figure 5. Expression of Transdominant TRRAP Mutants or TRRAP Antisense Blocks Transformation of Rat Embryo Fibroblasts by c-myc and
H-ras
(A) Expression of TRRAP protein fragments in 293 cells was assayed by Western blotting for the FLAG epitope. Duplicate plates of 293 cells
were transiently transfected with expression vectors encoding the TRRAP amino acids indicated. Lysates were resolved by 8% SDS-PAGE.
Molecular weight markers were run on the same gel and their positions indicated at left in kilodaltons.
(B) Primary REFs were transfected with expression vectors for c-myc and H-ras and, where indicated, expression vectors encoding fragments
of the TRRAP. The TRRAP fragments expressed in this assay encoded amino acids 270±599, 856±1134, 1261±1579, or 3402±3828, as labeled.
The number of transformed foci is expressed as a percentage of the number of foci obtained on c-myc/H-ras plates cotransfected with the
parental CMV-FLAG vector (CbF). Bars represent the average of 8 plates for CbF, 2 plates for 270±599, 2 plates for 856±1134, 4 plates for
1261±1579, and 4 plates for 3402±3828. Plate-to-plate variation in the absolute number of foci obtained with a given combination of vectors
was minimal (generally 5%±10%), and the average number of transformed foci on the CbF plates was 19.
(C and D) Primary REFs were transfected with expression vectors for c-myc, H-ras, and a CMV-driven expression vector containing 1.5 kb
of the 59 end of the TRRAP cDNA cloned in the antisense orientation (CbS TRRAP antisense). Transfection of the CMV expression vector
(CbS) containing no insert served as a control. The number of transformed foci is expressed as a percentage of foci obtained on plates
transfected with c-myc and H-ras and the CbS vector (D). (Each bar in [D] represents the average number of foci on 6 plates, with the average
number of transformed foci on CbS being 21.) One representative plate from both control (CbS) and antisense (CbS TRRAP antisense)
transfections were stained with crystal violet to visualize foci (C).
(E) Duplicate plates of 293 cells were transiently transfected with either CbS, CbS TRRAP antisense, or no DNA (mock), as indicated. Cells
were lysed at 48 hr posttransfection, and the concentration of total protein in the lysates was normalized. Fifty micrograms of protein from
each plate was resolved by 8% SDS-PAGE and blotted for TRRAP.
sense strategy serves as an independent confirmation levels correlates well with the 50%±80% transfection
efficiency routinely obtained with these 293 cells.of the essential role of TRRAP in c-Myc-dependent
transformation. To confirm that the TRRAP antisense An important consideration in both of the experiments
above is the potential toxicity of vectors that disrupt thevector was functioning by decreasing cellular levels of
the TRRAP protein, transient transfection of 293 cells function of an important pathway, such as that associ-
ated with c-Myc. To address this question, we tested ifwas performed. Duplicate plates of cells received either
the empty vector, the TRRAP antisense vector, or no any of theexpression vectors would inhibit the formation
of G418-resistant colonies of HeLa cells. When cotrans-DNA. Forty-eight hours after transfection, the cells were
lysed, the lysates normalized to equal protein concen- fected with pRSV-neo, approximately equal numbers of
colonies were obtained with all of the TRRAP proteintration, and the levels of TRRAP determined by Western
blotting. The presence of antisense TRRAP lowered fragment expression vectors and with theantisense vec-
tor, when compared to the correspondingempty vectorsTRRAP protein levels by approximately 60%±75%, rela-
tive to either the empty vector or mock transfection (Table 1). Thus, none of the vectors used to inhibit
TRRAP function aregenerally toxic for cells, and we infercontrols (Figure 5E). The 60%±75% reduction in TRRAP
Cell
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Table 1. TRRAP Antisense and Transdominant Mutants Fail to
Inhibit HeLa Cell Growth
G418-Resistant
Vector Transfected Colonies Per Plate
CbS 29
CbS/anti-sense TRRAP 28
CbF 18
CbF/TRRAP (270±599) 27
CbF/TRRAP (855±1134) 27
CbF/TRRAP (1261±1579) 18
CbF/TRRAP (3402±3828) 26
Duplicate plates of HeLa cells were cotransfected with 1 mg of
pRSV-neo and 3 mg of CMV-driven TRRAP vector, as indicated.
Transfected cells were selected in 400 mg/ml G418 for 14 days, at
which time the number of colonies per plate was determined. The
table presents data based on the average number of colonies on
duplicate plates.
that TRRAP becomes rate-limiting in Myc-dependent
transformation but not in normal cell growth where
TRRAP may be in excess.
TRRAP Is Essential for E1A-Mediated
Oncogenic Transformation
Previous studies demonstrated that overexpression of
the c-Myc N terminus could inhibit transformation by Figure 6. TRRAP Is Essential for Transformation by E1A and Inter-
the E1A oncogene and that inhibition was dependent acts with the Transactivation Domain of E2F-1 In Vivo
on MbII (Brough et al., 1995). To determine if TRRAP (A) Primary REFs were transfected with expression vectors for E1A,
was the rate-limiting cellular factor in this experiment, H-ras, and the TRRAP antisense expression vector described in
Figure 5 (CbS TRRAP antisense). Transfection of CbS containinga transformation assay of primary REFs transfected with
no insert served as a control. The number of transformed foci wasthe E1A and H-ras oncogenes was supplemented with
determined and expressed as a percentage of foci obtained onthe antisense TRRAP vector or with the empty vector
plates transfected with E1A, H-ras, and the CbS vector. (Each bar
as a control. Focus formation was monitored after 16±18 represents the average number of foci obtained on 4 plates, with
days posttransfection. The antisense TRRAP vector in- the average number of transformed foci in the presence of CbS
hibited E1A-mediated focus formation by greater than being 18.)
(B) Representative plates from an E1A/H-ras transformation assay70% (Figures 6A and 6B), comparable to the activity of
done in the presence of either CbS or TRRAP antisense vectorsthe same vector in Myc-mediated transformation. Thus,
were stained with crystal violet to visualize foci.TRRAP is an essential, rate-limiting factor for two dis-
(C) CMV-driven expression vectors were created encoding either a
tinct oncogenic pathways (c-Myc and E1A). FLAG epitope±tagged human E2F-1 protein, a similarly FLAG-
tagged E2F-1 protein with a point mutation (Y→C) at amino acid
411, or an E2F-1 mutant truncated at amino acid 373 (D373±437).TRRAP Binds to the Transactivation Domain
These vectors were transiently transfected into 293 cells. Lysatesof the E2F-1 Transcription Factor
from duplicate transfections were prepared and immunoprecipi-
Both the dominant inhibitory activity of the c-Myc N tated with anti-FLAG antibody. Precipitated proteins were resolved
terminus (Brough et al., 1995) and the similar inhibition by SDS-PAGE and Western blotted for either TRRAP (top) or the
by the TRRAP antisense vector are expected to create FLAG epitope of the transfected E2F-1 proteins (bottom). Lanes 1
and 2, lysates of cells transfected with an expression vector produc-a TRRAP loss-of-function, indicating that TRRAP is an
ing only the FLAG epitope. Lanes 3 and 4, lysate from cells express-essential component of the E1A pathway. It is well estab-
ing full-length E2F-1. Lanes 5 and 6, lysates from cells expressinglished that a major downstream effector of E1A is the
FLAG-E2F-1-Y411C. Lanes 7 and 8, lysates from cells expressing
E2F family of transcription factors. Because of the func- FLAG-E2F-1 truncated at amino acid 373. Size (in kilodaltons) at the
tional similarity between c-Myc and E2F, it was of inter- left was determined by coelectrophoeresis of protein MW markers
est to determine whether the TRRAP requirement in E1A (Novex).
transformation was due to a direct interaction between
TRRAP and E2F-1. Since the interaction of TRRAP with
c-Myc involves the transactivation domain, it was of transactivation domain of E2F-1 but preserves the DNA-
binding and DP dimerization domains, and similar C-ter-particular interest to test if the transactivation domain
of E2F-1 might also mediate binding. To this end, E2F-1 minal deletions of E2F-1 are inactive for most biological
activities. Transient expression of full-length E2F-1 inexpression vectors with FLAG epitope tags were con-
structed for effective immunoprecipitation. One vector 293 cells led to the coprecipitation of endogenous
TRRAP protein (Figure 6C, lanes 3 and 4). Notably, theexpressed full-length E2F-1, while a second vector ex-
pressed E2F-1 with a C-terminal truncation (deleting binding of TRRAP to E2F-1 was dependent on the trans-
activation domain because the C-terminal truncationamino acids 373±437). The latter construct deletes the
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mutant failed to coprecipitate endogenous TRRAP pro- The TRRAP protein is remarkably well conserved in
evolution, both in size and primary sequence (25% iden-tein (Figure 6C, lanes 7 and 8) even though the expres-
sion level was comparable to that of the full-length pro- tical/55% similar in S. cerevisiae, S. pombe, A. thaliana,
and C. elegans) over the entire 3800 amino acids in anytein. Thus, TRRAP binds to essential functional domains
of two different oncogenic transcription factors. pairwise comparison. This extensive identity indicates
that these genes are almost certainly true analogs andThe transactivation domain of E2F is also the site of
Rb binding, which masks transactivation. To determine not simply proteins that share a common structural mo-
tif. Interestingly, the TRRAP protein predates the exis-whether TRRAP binding to E2F-1 was distinguishable
from that of Rb, a third FLAG-tagged E2F-1 expression tence of c-Myc in evolution. Searches of the complete
S. cerevisiae genome database fail to identify any pro-vector was constructed that contained the Y411C muta-
tion. This mutation (and other missense mutations at tein with substantial homology to c-Myc, although sev-
eral DNA-binding proteins with B/HLH or B/Zip motifsthe same position) eliminates Rb binding and enhances
the ability of E2F to promote S phase progression (Helin are present. Based on these observations, we suggest
that the c-Myc protein evolved to recruit the TRRAPet al., 1993; Shan et al., 1996). Transient expression of
the E2F(Y411C) mutant in293 cells led tocoprecipitation protein to specific chromosomal sites in more complex
eukaryotes. This scenario has ample precedent in otherof endogenous TRRAP, and the binding was undimin-
ished compared to the wild-type E2F-1 protein (Figure pathways, with the most relevant being the Myc-related
repressor protein, Mad. The Mad protein represses gene6C, lanes 3±6). Since E2F-1 carrying the Y411C mutation
is still biologically active, it must retain the capacity to expression by recruiting the mammalian homolog of the
yeast corepressor, SIN3 (Ayer et al., 1995; Schreiber-recruit positive cofactors. Thus TRRAP binding to the
Y411C mutant is consistent with a role for TRRAP as an Agus et al., 1995). However, like Myc, there is no yeast
homolog of Mad, whereas the corepressor SIN3 is con-essential E2F-1 cofactor.
served. The most primitive homologs of c-Myc and E2F
identified to date are in Drosophila melanogaster, where
Discussion the domains linked to TRRAP binding are conserved
(Dynlacht et al., 1994; Ohtani and Nevins, 1994; Gallant
Through studies of an evolutionarily conserved and et al., 1996; Schreiber-Agus et al., 1997). This supports
functionally essential region of the c-Myc N terminus, our contention that an interaction with TRRAP was func-
we have identified a novel cofactor, designated TRRAP, tionally critical even at the earliest point in evolution.
whose interaction correlates with cell transformation by The N-terminal 92% of the TRRAP protein has no
this oncoprotein. Since both the TRRAP-binding and significant homology to any other protein in the data-
the DNA-binding domains of both c-Myc and E2F are base. In contrast, the C-terminal 300 amino acids of
essential for virtually all functionalactivities, the simplest TRRAP exhibits a striking homology to the ªPI-3 kinaseº
model is one in which these oncogenic transcription family, whose name derives from the catalytic subunit,
factors (as c-Myc/Max or E2F/DP heterodimers) recruit p110, of phosphoinositol-3 kinase, which is an enzyme
TRRAP to specific chromosomal sites to modulate gene involved in the generation of lipid second messengers
expression. The sequence of TRRAP has no homology and intracellular signaling (Toker and Cantley, 1997).
with proteins that have been implicated in gene regula- Although p110 is a lipid kinase, other members of the
tion and hence offers little insight into its precise func- family, including ATM and DNA-PKcs, are S/T protein
tion. TRRAP has no apparent DNA-binding motif, so it kinases with no lipid kinase activity (Hartley et al., 1995;
is unlikely that it binds to DNA in the absence of recruit- Baskaran et al., 1997). The sequence of the TRRAP PI-3
ment by c-Myc or other factors. Extensive searches for kinase domain adds a perplexing new facet to this enig-
motifs that might predict a function for the unique sec- matic family. Although the homology between TRRAP
tion of TRRAP (92% of the protein), such as acetylation, and the PI-3 kinase family is readily apparent, close
deacetylation, methylation, etc., have proven negative inspection of the TRRAP sequence reveals that this do-
to date. The lack of obvious motifs conferring biochemi- main may not be catalytically active in any of the five
cal activity and its unusually large size suggest that species discussed here. All other members of the ATM
TRRAP may serve as a scaffold for the assembly of a family contain the DXXXXN and DFG motifs that consti-
multiprotein complex at Myc/Max± and E2F/DP±binding tute critical residues of the catalytic site, and these resi-
sites in the genome. dues can be oriented with the same invariant motifs in
Genetic evidence indicates that the MbII domain of other kinases (Hunter, 1995; Taylor et al., 1995). Further-
c-Myc performs an essential function in cell transforma- more, missense or frameshift mutations that are pre-
tion, apoptosis, blocking differentiation, and other bio- dicted to abolish kinase activity yield biologically non-
logical activities associated with the c-myc oncogene functional proteins in those systems where they have
(see Introduction). There have been contradictory re- been tested (Zheng et al., 1995; Danska et al., 1996).
ports as to whether or not the MbII domain is required The absence of the DXXXXN and DFG motifs in TRRAP
for transcriptional regulation by c-Myc (Kato et al., 1990; (Figure 3B) may imply that this domain serves a function
Bello-Fernandez et al., 1993; Brough et al., 1995; Des- beyond its role as a kinase in other ATM family members.
barats et al., 1996). The most straightforward interpreta- It is of interest to note that at least one other member
tion of these inconsistent findings is that some, but not of the ATM family, DNA-PKcs, is recruited to DNA by a
all, Myc-regulated promoters may require the recruit- heterodimeric complex of DNA-binding proteins. ATM
ment of the TRRAP protein,although this model requires itself also functions in the nucleus, and a loss of ATM
function leads to hypersensitivity to irradiation and afurther experimentation.
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blotting with anti-FLAG or a rabbit anti-TRRAP antisera. Rabbit anti-substantially increased risk of cancer (Lavin and Shiloh,
TRRAP was generated by immunization with a peptide correspond-1996).
ing to the 26 C-terminal amino acids of human TRRAP. AntibodyThe homology between TRRAP and the ATM family
detection was performed using ECL (Amersham).
may predict a novel function for the c-Myc and E2F COLO 320 cells (ATCC) were grown in DMEM with 10% fetal calf
oncoproteins. Given the sequence-specific DNA binding serum. For the preparation of lysates, confluent 15 cm plates were
washed with PBS and then lysed in buffer F (Sommer et al., 1998).activity of these transcription factors and the binding of
Immunoprecipitations contained lysate from one-half of a single 15TRRAP to the transactivation domain, the simplest
cm plate and 5 mg of polyclonal rabbit anti-Max antisera (Santamodel for TRRAP function is that of a transcriptional
Cruz) or control rabbit immunoglobulin (Santa Cruz). Precipitationsadaptor protein. Yet no member of the ATM family has
were carried out as described above for 293 cells, except that West-
been previously linked to sequence-specific DNA-bind- ern blotting for c-Myc was performed using the monoclonal antibody
ing proteins. One model is that the ATM/PI-3 kinase 9E10.
Transformation assays involving REFs were performed as de-domain (noncatalytic in TRRAP) has been incorporated
scribed previously (Brough et al., 1995). Transfections includedinto proteins of many disparate families to mediate pro-
c-Myc expression vectors in the form of either CMV promoter±driventein±protein interactions and that its presence does not
FLAG/c-Myc (or various mutants thereof), or EMSV-c-myc (1 mg)predict any specific functional overlap. However, the
and H-ras (G12V) (1 mg), or the E1A expression vector p1A (1 mg)
involvement of severalATM-related proteins in the integ- andH-ras (G12V) (1 mg). Where indicated, transfections were supple-
rity and proper segregation of chromosomes suggests mented with either the CMV promoter±driven expression vectors
containing TRRAP cDNA fragments or with the empty vector (3 mg).the possibility that TRRAP may alter the chromatin
Following transfection, cells were maintained in DMEM containingaround specific target genes or that it may function in
4% fetal bovine serum, and foci were counted at day 12±14 post-a more global context in regulating chromosome struc-
transfection. Transfections were performed in duplicate, and theture or dynamics rather than at selected target genes.
data from multiple experiments were averaged.
Elucidation of the biochemical function of TRRAP may For HeLa cell transfection, pRSV-neo (1 mg) and CMV-driven
offer novel insight into c-Myc and E2F oncogenesis. TRRAP cDNA expression vectors (3 mg) were introduced by the
calcium phosphate method. Transfected cells were selected in 400
mg/ml G418 (GIBCO/BRL) for 14 days, at which time the number ofExperimental Procedures
colonies per plate was determined.
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